[Asia Economy Reporter Buaeri] SK Inc. C&C is unveiling an artificial intelligence (AI) that assists in the development of new drugs related to metabolic diseases such as diabetes and obesity.
On the 25th, SK Inc. C&C announced that it will launch the AI service 'iClue TDMD' in collaboration with Gachon University Gil Medical Center. iClue TDMD provides services to discover and validate targets such as genes and proteins that cause diseases. Target discovery is the first step in new drug development.
The AI helps find genes or proteins that cause metabolic diseases such as diabetes, obesity, fatty liver, and dyslipidemia, verify their roles, and then discover new drug candidate substances.
By accessing iClue TDMD and entering the name of the metabolic disease of interest or candidate targets in the search bar, a list of targets with a high likelihood of successful new drug development and analysis results are provided.
Yoon Dong-jun, head of the Healthcare Group at SK Inc. C&C, said, "iClue TDMD is a service that presents a new paradigm in the research and development field of new drug development, from target derivation to validation," adding, "We will continue to expand the AI service area related to new drug development targets and advance its functions."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
